Clinical Trial

Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

Name: Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL — clinical trial record (NCT07441993)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MZL-IIT-O

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naïve patients with marginal zone lymphoma.

Trial Details

NCT Number	NCT07441993
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Beijing Tongren Hospital
Conditions	Marginal Zone Lymphoma
Enrollment	30 participants
Start Date	2026-01-05
Primary Completion	2027-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-02